-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1 Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL NetworkClinically Relevant Abstract

Program: General Sessions
Session: Plenary Scientific Session
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, Clinical Research, B Cell lymphoma, Chemotherapy, Diseases, aggressive lymphoma, Therapies, Lymphoid Malignancies, young adult , Study Population, Human
Sunday, December 11, 2022, 2:00 PM-4:00 PM

Martin Dreyling, MD1, Jeanette K. Doorduijn, MD, PhD2, Eva Gine, MD, PhD3, Mats Jerkeman, MD, PhD4, Jan Walewski, MD5, Martin Hutchings, MD, PhD6*, Ulrich Mey, MD7,8, Jon Riise, MD, PhD9*, Marek Trneny, MD10, Vibeke K.J. Vergote11*, Melania Celli12*, Ofer Shpilberg, MD, MPH13*, Maria Gomes da Silva14*, Sirpa Leppa, MD, PhD15, Linmiao Jiang16*, Christiane Pott17*, Wolfram Klapper, MD18*, Döndü Gözel1*, Christian Schmidt, MD1*, Michael Unterhalt, MD, PhD1*, Marco Ladetto, MD19 and Eva Hoster1,20*

1Department of Internal Medicine III, LMU University Hospital Munich, Munich, Germany
2Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
3Department of Hematology, Hospital Clinic of Barcelona, IDIBAPS, CIBERONC, GELTAMO, Barcelona, Spain
4Division of Oncology, Skane University Hospital and Lund University, Lund, Sweden
5Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
6Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
7Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
8Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland
9Department of Oncology, Oslo University Hospital, Oslo, Norway
10First Department of Internal Medicine - Hematology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
11Department of Hematology, University Hospitals Leuven, Leuven, Belgium
12U.O. di Ematologia, Ospedale degli Infermi di Rimini, Rimini, Italy
13Institute of Hematology, Assuta Medical Centers, Tel-Aviv, Israel
14Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
15Department of Oncology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
16Institute for Medical Information Processing, Biometry and Epidemiology (IBE), LMU University Munich, Munich, Germany
17Clinic for Internal Medicine II - Haematology, Oncology, University Clinic Schleswig-Holstein, Kiel, Germany
18Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
19Department of Translational Medicine, University of Eastern Piedmont and Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
20Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany

On behalf of the European MCL Network

ML and EH contributed equally

Introduction: High-dose cytarabine-containing immunochemotherapy followed by autologous stem cell transplantation (ASCT) and rituximab maintenance represents the current standard of care for younger mantle cell lymphoma (MCL) patients. The BTK-inhibitor ibrutinib has shown promising efficacy in relapsed (Dreyling et al, Hemasphere 2022) and previously untreated older MCL patients (Wang et al., NEJM 2022). In 2016, the European MCL Network initiated the randomized, open-label, 3-arm TRIANGLE trial to evaluate the addition of ibrutinib to standard treatment (arm A+I) in comparison to the previous standard treatment (arm A) and an ibrutinib containing treatment without ASCT (arm I).

Patients and methods: Patients with previously untreated, advanced stage II-IV MCL, up to 65 years and suitable for high-dose cytarabine and ASCT were randomized 1:1:1 to the 3 trial arms A, A+I, and I in 13 European countries and Israel. Study treatment consisted of 3 cycles R-CHOP/R-DHAP without (arm A) or with ibrutinib added to R-CHOP cycles and 2 years maintenance (arms A+I, I). ASCT was planned for responding patients of arms A and A+I. Rituximab maintenance could be applied according to national guidelines in all responding patients irrespective of the trial arm. For the primary outcome, failure-free survival (FFS), stable disease at the end of induction, any progression, or death were counted as events. Three pairwise log-rank tests for FFS were monitored with regular pre-planned interim analyses maintaining each a one-sided 0.0167 significance level. A pre-defined decision criterion based on the statistical significance of the treatment comparisons was established to determine the future treatment recommendation. Secondary outcomes were overall response (OR), complete remission (CR), overall survival (OS), and grade 3-5 AEs.

Results: Between July 2016 and December 2020, 870 patients were randomized to A (n=288), A+I (n=292), and I (n=290). Median age was 57 years (range 27-68), 76% of the patients were male, 87% had stage IV, and 58%/27%/15% had low/intermediate/high risk MIPI. OR and CR rates were 94% and 36% of 272 evaluable patients in arm A (R-CHOP/R-DHAP) as compared to 98% and 45% of 559 evaluable patients in the combined A+I/I arms (ibrutinib-R-CHOP/R-DHAP). After a median follow-up of 31 months, A failed to show superiority over I in terms of FFS with 3-year FFS 72% (A) vs. 86% (I; p=0.9979, hazard ratio: 1.77, Figure 1A). A+I was superior to A in terms of FFS with 3-year FFS 88% (A+I) vs. 72% (A; p=0.0008, hazard ratio: 0.52). Subgroup analyses by the intention to apply rituximab maintenance did not change the main results on the lack of superiority of A vs. I and the superiority of A+I vs. A . Statistical monitoring for the FFS comparison of A+I vs. I is still ongoing. Three-year OS was 86% in A, 91% in A+I, and 92% in I (Figure 1B). There were no substantial differences in the occurrence of grade 3-5 AEs during induction with R-CHOP/R-DHAP vs ibrutinib-R-CHOP/R-DHAP (neutropenia: 47%/49% of patients, leukopenia: 15%/15%, febrile neutropenia: 9%/12%, infections and infestations: 9%/12%, cardiac disorders: 2%/3%). The two ASCT-containing arms did not substantially differ in grade 3-5 AEs (A/A+I: neutropenia: 36%/33%, febrile neutropenia: 20%/22%, leukopenia: 17%/17%, infections and infestations: 17%/20%). In contrast, during maintenance, there were substantially more grade 3-5 AEs in A+I as compared to A and I (A+I/A/I: neutropenia: 44%/17%/23%, leukopenia: 4%/2%/2%, febrile neutropenia: 6%/3%/3%, infections and infestations: 25%/13%/19%, cardiac disorders: 3%/1%/4%).

Conclusions: The addition of ibrutinib during induction and as maintenance with or without ASCT showed strong efficacy with acceptable toxicity. It has been clearly demonstrated that the current standard high-dose regimen is not superior to the new ibrutinib-containing regimen without ASCT. More follow-up is needed to clarify the role of ASCT in the context of ibrutinib-containing treatment. However, the current results already support the use of ibrutinib in the first-line treatment of younger MCL patients.

Figure 1A: FFS (primary outcome) and B: OS according to randomized trial arm A (R-CHOP/R-DHAP followed by ASCT), A+I (ibrutinib-R-CHOP/R-DHAP followed by ASCT and ibrutinib maintenance) and I (ibrutinib-R-CHOP/R-DHAP followed by ibrutinib maintenance)

Disclosures: Dreyling: Lilly/Loxo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead/Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Abbvie: Research Funding; Beigene: Consultancy. Doorduijn: Eli Lilly/Loxo: Honoraria, Membership on an entity's Board of Directors or advisory committees. Gine: Kite, a Gilead Company: Consultancy, Honoraria; Genmab: Honoraria; Janssen: Honoraria, Research Funding. Jerkeman: Novartis: Honoraria; Orion: Honoraria; Incyte: Honoraria; Kite/Gilead: Consultancy, Honoraria, Research Funding; Genmab: Honoraria; AstraZeneca: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding. Walewski: AstraZeneca: Research Funding; Celgene/BMS: Research Funding; Epizyme: Research Funding; Gilead: Research Funding; GSK: Research Funding; Incyte: Research Funding; Janssen-Cilag: Research Funding; Karyopharm: Research Funding; Morphosys: Research Funding; MSD: Research Funding; Nanovector: Research Funding; Novartis: Consultancy; Regeneron: Research Funding; Roche: Honoraria; Seagen: Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding. Hutchings: Genmab: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Novartis: Research Funding; Incyte: Research Funding; Takeda: Consultancy, Research Funding; Genentech: Research Funding; Celgene, Genentech, Genmab, Incyte, Janssen, Novartis, Roche, Takeda: Research Funding; AbbVie, Celgene, Genmab, Janssen, Roche, Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; AbbVie: Consultancy. Mey: Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy; Amgen: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; BMS/Celgene: Consultancy; Pfizer: Consultancy; Beigene: Consultancy; Novartis: Consultancy; Gilead: Consultancy; Incyte: Consultancy. Riise: AstraZeneca: Consultancy. Trneny: Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Zentiva: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Gilead Sciences: Consultancy, Honoraria; Hoffman-La Roche: Consultancy, Honoraria, Research Funding. Vergote: Janssen: Honoraria; Gilead/Kite: Consultancy; Celgene/BMS: Consultancy; Beigene: Consultancy. Gomes da Silva: Janssen: Speakers Bureau; Gilead Genesis: Research Funding; Janssen, Gilead Sciences, MSD, Celgene, Roche, Takeda, Novartis, ADC Therapeutics: Consultancy; Roche: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding. Leppa: Novartis: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Research Funding; Gilead Sciences: Consultancy, Honoraria; BMS: Consultancy, Research Funding; Bayer: Research Funding; Orion Pharma: Consultancy; Pfizer: Consultancy; Beigene: Consultancy; Genmab: Research Funding; Nordic Nanovector: Research Funding; Incyte: Consultancy, Honoraria. Schmidt: Janssen: Other: Travel Support; Bayer Healthcare: Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support; Kite Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Support. Ladetto: Sandoz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead/Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gentili: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSKI: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Eusapharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AMGEN: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Acerta: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

OffLabel Disclosure: ibrutinib in first-line treatment of mantle cell lymphoma

See more of: Plenary Scientific Session
See more of: General Sessions